Kaken Pharmaceutical Co., Ltd.
Other OTCTotal Valuation
Kaken Pharmaceutical Co., Ltd. carries a market capitalization of 984.58M, placing it among publicly traded companies globally. Its enterprise value stands at 69.55B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 984.58M |
| Enterprise Value | 69.55B |
Share Statistics
Kaken Pharmaceutical Co., Ltd. currently has 37.87M shares outstanding.
| Shares Outstanding | 37.87M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Kaken Pharmaceutical Co., Ltd. trades at a trailing price-to-earnings ratio of 37.83. The price-to-sales ratio is 4.17, and the price-to-book ratio stands at 0.91.
| PE Ratio | 37.83 |
| PS Ratio | 4.17 |
| PB Ratio | 0.91 |
| P/TBV Ratio | 1.02 |
| P/FCF Ratio | N/A |
| P/OCF Ratio | N/A |
Enterprise Valuation
On an enterprise value basis, Kaken Pharmaceutical Co., Ltd. trades at an EV/EBITDA multiple of 17.38 and an EV/FCF ratio of 8,078.84. The EV/Sales ratio of 1.94 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 17.38 provides insight into valuation relative to core operating earnings.
| EV / Sales | 1.94 |
| EV / EBITDA | 17.38 |
| EV / EBIT | 17.38 |
| EV / FCF | 8,078.84 |
Financial Position
Kaken Pharmaceutical Co., Ltd. maintains a current ratio of 5.18, meaning it holds 5.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 2.49, indicating elevated leverage, while an interest coverage ratio of 444.67 demonstrates strong ability to service its debt obligations.
| Current Ratio | 5.18 |
| Quick Ratio | 3.55 |
| Debt / Equity | 2.49 |
| Debt / EBITDA | 0.96 |
| Interest Coverage | 444.67 |
Financial Efficiency
Kaken Pharmaceutical Co., Ltd. posts a return on equity of 2.51 and a return on invested capital of 2.47.
| Return on Equity (ROE) | 2.51 |
| Return on Assets (ROA) | 2.21 |
| Return on Invested Capital (ROIC) | 2.47 |
| Return on Capital Employed (ROCE) | 2.46 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 0.98 |
Taxes
Over the trailing twelve months, Kaken Pharmaceutical Co., Ltd. has paid 180.00M in income taxes, reflecting an effective tax rate of 4.35.
| Income Tax | 180.00M |
| Effective Tax Rate | 4.35 |
Stock Price Statistics
Kaken Pharmaceutical Co., Ltd.'s stock has declined approximately -7.44037% over the past 52 weeks. The 50-day moving average sits at 26.00, while the 200-day moving average is 25.81.
| Beta (5Y) | N/A |
| 52-Week Price Change | -7.44037% |
| 50-Day Moving Average | 26.00 |
| 200-Day Moving Average | 25.81 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Kaken Pharmaceutical Co., Ltd. generated 35.87B in revenue and converted that into 3.96B in net income, yielding earnings per share of 104.52. EBITDA reached 4.00B, while operating income came in at 4.00B.
| Revenue | 35.87B |
| Gross Profit | 18.82B |
| Operating Income | 4.00B |
| Pretax Income | 4.14B |
| Net Income | 3.96B |
| EBITDA | 4.00B |
| EBIT | 4.00B |
| Earnings Per Share (EPS) | 104.52 |
Balance Sheet
Kaken Pharmaceutical Co., Ltd. holds 83.99B in cash and equivalents against 3.85B in total debt, resulting in a net debt position of -63.44B. Total book value stands at 163.80B, with working capital of 99.00B providing operational flexibility.
| Cash & Cash Equivalents | 83.99B |
| Total Debt | 3.85B |
| Net Debt | -63.44B |
| Equity (Book Value) | 163.80B |
| Book Value Per Share | 4,325.72 |
| Working Capital | 99.00B |
Margins
Kaken Pharmaceutical Co., Ltd. operates with a gross margin of 52.46, reflecting its pricing power and cost economics. The operating margin of 11.16 and net profit margin of 11.03 provide insight into operational efficiency.
| Gross Margin | 52.46 |
| Operating Margin | 11.16 |
| Pretax Margin | 11.54 |
| Profit Margin | 11.03 |
| EBITDA Margin | 11.16 |
Scores
Kaken Pharmaceutical Co., Ltd. posts an Altman Z-Score of 4.77, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 4.77 |